CERAD was funded by the National Institute on Aging to develop uniform assessments for Alzheimer’s disease. Based on guidelines then present the main standardized and evaluated assessments produced for AD were: clinical, neuropsychological, neuropathological, service use, family history, and the Behavior Rating Scale for Dementia (BRSD). The neuropsychological (also relevant for assessing mild cognitive impairment (MCI)) and neuropathological assessments, and the BRSD enjoy particularly wide use. Up to eight years of data for 463 controls and 1,094 AD cases (890 White, 204 African American) are available. Most data were gathered before the advent of antidementia agents. Both measures and data are available.
Web site and access information: http://cerad.mc.duke.edu 
Languages: English, Arabic, Bulgarian, Chinese (Cantonese, Mandarin), Dutch, Finnish, French, German, Hindi (adapted), Italian, Japanese, Korean, Norwegian, Polish, Portuguese, Russian, Spanish. Sections in Hebrew, Swedish.
Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, Mellits ED, Clark C, and the CERAD investigators. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part 1. Clinical and Neuropsychological Assessment of Alzheimer's Disease. Neurology 1989; 39:1159-1165.
Fillenbaum GG, van Belle G, Morris JC, Mohs RC, Mirra SS, Davis PC, Tariot PN, Silverman JM, Clark CM, Welsh-Bohmer KA, Heyman A. CERAD (Consortium to Establish a Registry for Alzheimer’s Disease): The first 20 years. Alzheimer's and Dementia: The Journal of the Alzheimer's Association 2008;4(2): 96-109. PMCID: PMC2808763